The stock of Clearside Biomedical Inc (NASDAQ: CLSD) has increased by 5.89 when compared to last closing price of 0.85.Despite this, the company has seen a gain of 1.29% in its stock price over the last five trading days. globenewswire.com reported 2025-03-06 that – CLS-AX Phase 3 Program Designed to Maximize Commercial Potential in Wet AMD – – Flexible Dosing and Extended Duration would be Important Differentiators from Existing Approved Therapies and Other Tyrosine Kinase Inhibitors in Development – ALPHARETTA, Ga., March 06, 2025 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the receipt of the formal meeting minutes from its recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) relating to CLS-AX (axitinib injectable suspension) for the treatment of neovascular age-related macular degeneration (wet AMD).
Is It Worth Investing in Clearside Biomedical Inc (NASDAQ: CLSD) Right Now?
Company’s 36-month beta value is 2.14.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CLSD is 64.31M, and currently, short sellers hold a 0.89% ratio of that floaft. The average trading volume of CLSD on March 06, 2025 was 252.73K shares.
CLSD’s Market Performance
The stock of Clearside Biomedical Inc (CLSD) has seen a 1.29% increase in the past week, with a -7.99% drop in the past month, and a -17.41% fall in the past quarter. The volatility ratio for the week is 8.87%, and the volatility levels for the past 30 days are at 7.56% for CLSD. The simple moving average for the last 20 days is -6.87% for CLSD’s stock, with a simple moving average of -18.47% for the last 200 days.
Analysts’ Opinion of CLSD
Many brokerage firms have already submitted their reports for CLSD stocks, with Chardan Capital Markets repeating the rating for CLSD by listing it as a “Buy.” The predicted price for CLSD in the upcoming period, according to Chardan Capital Markets is $6 based on the research report published on August 21, 2024 of the previous year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CLSD reach a price target of $5. The rating they have provided for CLSD stocks is “Outperform” according to the report published on June 25th, 2024.
Wedbush gave a rating of “Outperform” to CLSD, setting the target price at $9 in the report published on December 15th of the previous year.
CLSD Trading at -5.68% from the 50-Day Moving Average
After a stumble in the market that brought CLSD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.54% of loss for the given period.
Volatility was left at 7.56%, however, over the last 30 days, the volatility rate increased by 8.87%, as shares sank -15.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.16% lower at present.
During the last 5 trading sessions, CLSD rose by +2.39%, which changed the moving average for the period of 200-days by -30.54% in comparison to the 20-day moving average, which settled at $0.9669. In addition, Clearside Biomedical Inc saw -5.24% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLSD starting from Thorp Clay, who purchase 15,000 shares at the price of $0.92 back on Feb 24 ’25. After this action, Thorp Clay now owns 176,141 shares of Clearside Biomedical Inc, valued at $13,800 using the latest closing price.
Chong Ngai Hang Victor, the Chief Medical Officer of Clearside Biomedical Inc, purchase 36,500 shares at $1.00 during a trade that took place back on Nov 01 ’24, which means that Chong Ngai Hang Victor is holding 100,000 shares at $36,500 based on the most recent closing price.
Stock Fundamentals for CLSD
Current profitability levels for the company are sitting at:
- -3.2 for the present operating margin
- 0.99 for the gross margin
The net margin for Clearside Biomedical Inc stands at -4.14. The total capital return value is set at -1.05.
Based on Clearside Biomedical Inc (CLSD), the company’s capital structure generated -0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -24.14. The debt to equity ratio resting at -0.02. The interest coverage ratio of the stock is -2.6.
Currently, EBITDA for the company is -23.06 million with net debt to EBITDA at 0.59. When we switch over and look at the enterprise to sales, we see a ratio of 7.22. The receivables turnover for the company is 9.78for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.49.
Conclusion
In a nutshell, Clearside Biomedical Inc (CLSD) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
